The new 300µL interlocked robotic arm machine (RAM) vial with 9mm thread finish from J G Finneran Associates based in Vineland, NJ, US is aimed at researchers tasked with managing a high number of chromatography sample vials in their laboratories.
Composed of a clear or amber Type I borosilicate glass, the vial and insert are fused together keeping the insert permanently in place. This enables accurate automated injection and eliminates contamination risk around the seam or space between the neck of the vial and the insert. The interlocked RAM vial arrives ready to use saving valuable time in the laboratory.
The vial has been designed to work in robotic arm autosamplers such as those available from Agilent Technologies and others. Robotic arms can easily grasp the 12mm x 32mm outer dimensions of the vial. Chromatography samples are contained in a clear Type I borosilicate glass 300µL conical tip insert. The interlocked RAM vial includes a marking spot, which can be written on with a #2 pencil. The vial is also available with a 9mm screw thread closure.
Interlocked RAM vial provides safe sample containment
For researchers managing a high number of chromatography sample vials
You may also like
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
How intelligent checkweighers offer improved productivity in pharmaceutical manufacturing
Read morePrecise weighing, automated reporting and tailored handling help pharmaceutical producers reduce waste, streamline compliance processes and maintain reliable output across demanding production lines
Trending Articles
You may also like
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Manufacturing
How intelligent checkweighers offer improved productivity in pharmaceutical manufacturing
Precise weighing, automated reporting and tailored handling help pharmaceutical producers reduce waste, streamline compliance processes and maintain reliable output across demanding production lines
Manufacturing
Shilpa CDMO invests $50m to expand peptide manufacturing capacity in India
The CDMO is investing $50m in additional solid-phase peptide synthesis capacity and a new commercial manufacturing line at its Raichur campus, expanding its capabilities to meet demand for GLP-1s and increasingly complex peptide therapeutics across oncology and rare diseases
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Manufacturing
From speed to strategy: how UK life sciences should respond to China’s rise
A group of biotech founders, big pharma leaders, clinical and CMC specialists, and CDMO executives gathered at a recent dinner sponsored by AsymChem to discuss a question now sitting in many boardrooms: what is China’s maturing biopharma ecosystem doing to the global industry, and how should UK companies respond?